The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy

Author： Nordmann A.J.   Krahn M.   Logan A.G.   Naglie G.   Detsky A.S.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.8, 2003-01, pp. : 573-585

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ACE inhibitors not worth it as first-line therapy in hypertension

By  

Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

ACE inhibitors not worth it as first-line therapy in hypertension

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 413, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

By Spalding James R.  

PharmacoEconomics, Vol. 24, Iss. 12, 2006-01 ,pp. : 1221-1232

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma

By Ya-Chen Tina Shih  

PharmacoEconomics, Vol. 25, Iss. 7, 2007-01 ,pp. : 577-590

Adis International

Access to resources Recommend Favorite

From Randomised Clinical Trials to Clinical Practice: A Pragmatic Cost-Effectiveness Analysis of Paclitaxel in First-Line Therapy for Advanced Ovarian Cancer

By Samuel Limat  

PharmacoEconomics, Vol. 22, Iss. 10, 2004-01 ,pp. : 633-641

Adis International

Access to resources Recommend Favorite